Gilead Sciences (GILD) has completed its previously announced acquisition of Germany-based Tubulis, a biotechnology company developing antibody-drug conjugates or ADCs, for $3.15 billion, Gilead said Thursday.
The transaction entitles Tubulis to up to $1.85 billion in contingent milestone payments, according to the statement.
Tubulis will remain based in Munich, Germany to establish its ADC innovation center, Gilead said.
Price: $130.53, Change: $-0.16, Percent Change: -0.12%
(Updates with dividend in the penultimate paragraph and stock movement in the last.)EnerSys (ENS) reported fiscal Q4 adjusted earnings late Wednesday of $3.19 per diluted share, up from $2.97 a year earlier.Analysts polled by FactSet expected $2.99.Revenue in the three months ended March 31 rose to $988 million from $974.8 million a year earlier.Analysts surveyed by FactSet expected $973.8 million.EnerSys expects Q1 revenue of $915 million to $955 million.Analysts polled by FactSet expect $914.6 million.The company maintained its quarterly dividend at $0.2625 a share, payable July 2 to stockholders of record June 19.EnerSys shares rose 6.7% in after-hours trading.
E.l.f. Beauty (ELF) reported fiscal Q4 adjusted net income late Wednesday of $0.32 per diluted share, down from $0.78 a year earlier.Analysts polled by FactSet expected $0.29.Revenue for the quarter ended March 31 rose to $449.3 million from $332.6 million a year earlier.Analysts polled by FactSet expected $423.1 million.For fiscal 2027, the company expects adjusted EPS of $3.27 to $3.32 on revenue of $1.84 billion to $1.87 billion. Analysts expect $3.61 and $1.86 billion, respectively.Shares of the company rose 6% in after-hours activity.
GUIDANCE: (INTU) Intuit Expects Fiscal 2026 Revenue Range $21.341B-$21.374B, vs. FactSet Est of $21.24B